{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:11:18Z","timestamp":1767143478928,"version":"build-2238731810"},"update-to":[{"DOI":"10.1007\/s13277-012-0401-8","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T00:00:00Z","timestamp":1334880000000}}],"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T00:00:00Z","timestamp":1334880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s13277-012-0401-8","type":"journal-article","created":{"date-parts":[[2012,4,19]],"date-time":"2012-04-19T06:47:38Z","timestamp":1334818058000},"page":"1505-1510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["RETRACTED ARTICLE: A translocator protein ligand PK11195 shows antigrowth activity in human choriocarcinoma cells"],"prefix":"10.1007","volume":"33","author":[{"given":"Noriyuki","family":"Takai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoko","family":"Kira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terukazu","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshie","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaei","family":"Nasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Midori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Narahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,20]]},"reference":[{"key":"401_CR1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1525-1438.1997.00409.x","volume":"7","author":"WB Jones","year":"1997","unstructured":"Jones WB, Cardinale C, Lewis Jr JL. Management of the high-risk gestational trophoblastic disease\u2014the Memorial Hospital experience. Int J Gynecol Cancer. 1997;7:27\u201333.","journal-title":"Int J Gynecol Cancer"},{"key":"401_CR2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0090-8258(84)90177-X","volume":"19","author":"RS Berkowitz","year":"1984","unstructured":"Berkowitz RS, Goldstein DP, Bernstein MR. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol Oncol. 1984;19:173\u201381.","journal-title":"Gynecol Oncol"},{"key":"401_CR3","first-page":"565","volume":"55","author":"EA Surwit","year":"1980","unstructured":"Surwit EA, Hammond CB. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet Gynecol. 1980;55:565\u201370.","journal-title":"Obstet Gynecol"},{"key":"401_CR4","first-page":"1388","volume":"62","author":"D Decaudin","year":"2002","unstructured":"Decaudin D, Castedo M, Nemati F, et al. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 2002;62:1388\u201393.","journal-title":"Cancer Res"},{"key":"401_CR5","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1054\/bjoc.2001.2181","volume":"85","author":"K Maaser","year":"2001","unstructured":"Maaser K, H\u00f6pfner M, Jansen A, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human colorectal cancer cells. Br J Cancer. 2001;85:1771\u201380.","journal-title":"Br J Cancer"},{"key":"401_CR6","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/ijc.10724","volume":"102","author":"AP Sutter","year":"2002","unstructured":"Sutter AP, Maaser K, H\u00f6pfner M, et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int J Cancer. 2002;102:318\u201327.","journal-title":"Int J Cancer"},{"key":"401_CR7","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/0024-3205(83)90062-0","volume":"32","author":"G Fur Le","year":"1083","unstructured":"Le Fur G, Perrier ML, Vaucher N. Peripheral benzodiazepine binding sites: effect of PK 11195, 1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide. I. In vitro studies. Life Sci. 1083;32:1839\u201347.","journal-title":"Life Sci"},{"key":"401_CR8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.tips.2006.06.005","volume":"27","author":"V Papadopoulos","year":"2006","unstructured":"Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18\u00a0kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402\u20139.","journal-title":"Trends Pharmacol Sci"},{"key":"401_CR9","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1038\/sj.onc.1208907","volume":"24","author":"RA Gonzalez-Polo","year":"2005","unstructured":"Gonzalez-Polo RA, Carvalho G, Braun T, et al. PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepine receptor. Oncogene. 2005;24:7503\u201313.","journal-title":"Oncogene"},{"key":"401_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.186.1.25","volume":"186","author":"SA Susin","year":"1997","unstructured":"Susin SA, Zamzami N, Castedo M, et al. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas\/APO-1\/CD95- and ceramide-induced apoptosis. J Exp Med. 1997;186:25\u201337.","journal-title":"J Exp Med"},{"key":"401_CR11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0304-4157(95)00003-A","volume":"1241","author":"M Zoratti","year":"1995","unstructured":"Zoratti M, Szab\u00f2 I. The mitochondrial permeability transition. Biochim Biophys Acta. 1995;1241:139\u201376.","journal-title":"Biochim Biophys Acta"},{"key":"401_CR12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1022945107762","volume":"8","author":"JD Ly","year":"2003","unstructured":"Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis. 2003;8:115\u201328.","journal-title":"Apoptosis"},{"key":"401_CR13","first-page":"256","volume":"54","author":"D Jong De","year":"1994","unstructured":"De Jong D, Prins FA, Mason DY, et al. Subcellular localization of the bcl-2 protein in malignant and normal lymphoid cells. Cancer Res. 1994;54:256\u201360.","journal-title":"Cancer Res"},{"key":"401_CR14","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm0697-614","volume":"3","author":"G Kroemer","year":"1997","unstructured":"Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997;3:614\u201320.","journal-title":"Nat Med"},{"key":"401_CR15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/toxsci\/kfg052","volume":"74","author":"DE Muscarella","year":"2003","unstructured":"Muscarella DE, O'Brien KA, Lemley AT, et al. Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. Toxicol Sci. 2003;74:66\u201373.","journal-title":"Toxicol Sci"},{"key":"401_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1023\/A:1027339418683","volume":"17","author":"T Hirsch","year":"1997","unstructured":"Hirsch T, Marzo I, Kroemer G. Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep. 1997;17:67\u201376.","journal-title":"Biosci Rep"},{"key":"401_CR17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1472-8206.1989.tb00679.x","volume":"3","author":"A Ferry","year":"1989","unstructured":"Ferry A, Jaillon P, Lecocq B, et al. Pharmacokinetics and effects on exercise heart rate of PK 11195 (52028 RP), an antagonist of peripheral benzodiazepine receptors, in healthy volunteers. Fundam Clin Pharmacol. 1989;3:383\u201392.","journal-title":"Fundam Clin Pharmacol"},{"key":"401_CR18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-2007-1014425","volume":"24","author":"M Ansseau","year":"1991","unstructured":"Ansseau M, von Frenckell R, Cerfontaine JL, et al. Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. Pharmacopsychiatry. 1991;24:8\u201312.","journal-title":"Pharmacopsychiatry"},{"key":"401_CR19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/1078-0432.CCR-03-0100","volume":"10","author":"N Takai","year":"2004","unstructured":"Takai N, Desmond JC, Kumagai T, et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res. 2004;10:1141\u20139.","journal-title":"Clin Cancer Res"},{"key":"401_CR20","first-page":"637","volume":"21","author":"N Takai","year":"2008","unstructured":"Takai N, Ueda T, Nishida M, et al. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637\u201343.","journal-title":"Int J Mol Med"},{"key":"401_CR21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/(SICI)1097-4547(19970615)48:6<563::AID-JNR9>3.0.CO;2-8","volume":"48","author":"G Rimon","year":"1997","unstructured":"Rimon G, Bazenet CE, Philpott KL, et al. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563\u201370.","journal-title":"J Neurosci Res"},{"key":"401_CR22","first-page":"6437","volume":"61","author":"Y Chen","year":"2001","unstructured":"Chen Y, Kramer DL, Diegelman P, et al. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437\u201344.","journal-title":"Cancer Res"},{"key":"401_CR23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2008.08.004","volume":"111","author":"N Takai","year":"2008","unstructured":"Takai N, Ueda T, Nasu K, et al. Erucylphosphocholine shows a strong anti-growth activity in human endometrial and ovarian cancer cells. Gynecol Oncol. 2008;111:336\u201343.","journal-title":"Gynecol Oncol"},{"key":"401_CR24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.39.1.295","volume":"39","author":"D Johnson","year":"1999","unstructured":"Johnson D, Walker C. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295\u2013312.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"401_CR25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0092-8674(94)90540-1","volume":"79","author":"C Sherr","year":"1994","unstructured":"Sherr C. G1 phase progression: cycling on cue. Cell. 1994;79:551\u20135.","journal-title":"Cell"},{"key":"401_CR26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00432-002-0328-3","volume":"128","author":"N Kyushima","year":"2002","unstructured":"Kyushima N, Watanabe J, Hata H, et al. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol. 2002;128:307\u201312.","journal-title":"J Cancer Res Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s13277-015-3646-1","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"record-id":"712"},{"DOI":"10.1007\/s13277-012-0401-8","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T00:00:00Z","timestamp":1334880000000}},{"DOI":"10.1007\/s13277-015-3646-1","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T00:00:00Z","timestamp":1436054400000}}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0401-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-012-0401-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-012-0401-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T11:24:42Z","timestamp":1559474682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-012-0401-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,20]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s13277-012-0401-8","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,20]]}}}